Our research is based on an understanding of the mechanism of iPS reprogramming, direct conversion and the generation of patient-specific stem cells for future cell therapy. The aim is to develop innovative cell therapeutic methods for clinical applications and possible solutions for degenerative and currently incurable disease. In addition, iPS cells and direct conversion can also be used for innovative techniques of drug screening and toxicity tests. Therefore, the therapeutic potential of iPS cell and direct converted cells are very promising.
Moreover, we are collaborating with the Max Planck Institute for Molecular Biomedicine (MPI-MBM) located in Muenster, Germany. This collaboration will create synergic effects that will be mutually beneficial. Continuously seeking new areas of collaboration, we will reach out to become a world-class stem cell research group.